Proteinuria: Difference between revisions

Jump to navigation Jump to search
Line 396: Line 396:
*[[Microalbuminuria]]
*[[Microalbuminuria]]
*[[List of terms associated with diabetes]]
*[[List of terms associated with diabetes]]
===Causes by Organ System===
<small>
{| style="width:82%; height:100px" border="1"
| style="width:25%" bgcolor="lightsteelblue" ; border="1" | '''Cardiovascular'''
| style="width:75%" bgcolor="beige" ; border="1" |[[Amyloidosis]], benign orthostatic proteinuria, [[constrictive pericarditis]], [[dehydration]], [[eclampsia]], [[hypertension]], [[Nutcracker syndrome]], [[preeclampsia]], [[renal artery stenosis]], [[renal vein thrombosis]], [[shock ]] , [[subacute bacterial endocarditis]], [[tricuspid insufficiency]]
|-
|- bgcolor="lightsteelblue"
| '''Chemical/Poisoning'''
| bgcolor="beige" | [[Nitrosourea  compounds]], [[mercury]], [[cadmium]], trichloroethlene, [[bromobenzene]] , [[chloroform]], aristolochic acids , paraquat, diquat, [[ethylene glycol]]
|-
|- bgcolor="lightsteelblue"
| '''Dental'''
| bgcolor="beige" | No underlying causes
|-
|- bgcolor="lightsteelblue"
| '''Dermatologic'''
| bgcolor="beige" | [[Scleroderma]]
|-
|- bgcolor="lightsteelblue"
| '''Drug Side Effect'''
| bgcolor="beige" | [[Acetaminophen and Oxycodone]], [[Aflibercept]], [[anticonvulsants]], [[Artemether and lumefantrin]], [[bevacizumab]], [[captopril]], [[carmustine]], [[caspofungin]], [[cisplatin]], [[deferasirox]], [[diflunisal]], [[febuxostat]], [[gemcitabine]], [[gold]], [[heavy metal ingestion]], [[heroin]], [[Interferon gamma]], [[Lenvatinib]], [[Lincomycin Hydrochloride]], [[lomustine]], [[micafungin]], [[mithramycin]], [[NSAIDS]], [[Olsalazine]], [[Oxaprozin]], [[pazopanib]], [[penicillamine]], [[pramipexole]], [[rifaximin]], [[Sodium aurothiomalate]], [[Sorafenib]], [[Streptozocin]], [[sulfasalazine]], [[sulindac]], [[Telavancin hydrochloride]], [Thalidomide]], [[Tolmetin]] , [[Ziv-aflibercept]]
|- bgcolor="lightsteelblue"
| '''Ear Nose Throat'''
| bgcolor="beige" | No underlying causes
|-
|- bgcolor="lightsteelblue"
| '''Endocrine'''
| bgcolor="beige" |[[Diabetes mellitus]], [[hypothyroidism]]
|-
|- bgcolor="lightsteelblue"
| '''Environmental'''
| bgcolor="beige" |[[Allergens]], [[irradiation]]
|-
|- bgcolor="lightsteelblue"
| '''Gastroenterologic'''
| bgcolor="beige" | [[Cirrhosis of liver]], [[Wilson's disease]], [[hemochromatosis]]
|-
|- bgcolor="lightsteelblue"
| '''Genetic'''
| bgcolor="beige" | [[Alport syndrome]], [[Alström syndrome]], [[aminoaciduria]], [[amyloidosis]], [[Balkan nephropathy]], connatal tubulopathies, [[cystinosis]], [[Dent disease]], [[diabetes mellitus]], [[Fabry's disease]], familial mediterranean fever, galactosemia, [[glycogen storage disease|glycogen storage disease type I]], [[hepatorenal tyrosinemia]], [[hereditary fructose intolerance]], [[Carnevale-Canun-Mendoza syndrome|idiopathic multicentric osteolysis]], [[Imerslund-Grasbeck syndrome]], [[Lecithin cholesterol acyltransferase deficiency]], [[Nail-patella syndrome]], [[polycystic kidney disease ]] , [[recurrent hereditary polyserositis]], [[Wilson's disease]], [[hypophosphatemia|X-linked hypophosphatemia]]
|-
|- bgcolor="lightsteelblue"
| '''Hematologic'''
| bgcolor="beige" | No underlying causes
|-
|- bgcolor="lightsteelblue"
| '''Iatrogenic'''
| bgcolor="beige" | No underlying causes
|-
|- bgcolor="lightsteelblue"
| '''Infectious Disease'''
| bgcolor="beige" | [[Epstein-barr virus]],  [[helminthic]], [[hepatitis B]], [[HIV]], [[infectious mononucleosis]], [[Legionella pneumophila]], [[leprosy]], [[malaria]],  [[poststreptococcal glomerulonephritis]], [[Prostitis]], [[pyelonephritis|acute Pyelonephritis]], [[Subacute bacterial endocarditis]], [[toxoplasmosis]], [[urinary tract infection]],  [[viral illness]], [[yellow fever]], [[tuberculosis|genitourinary tuberculosis]]
|- bgcolor="lightsteelblue"
| '''Musculoskeletal/Orthopedic'''
| bgcolor="beige" | [[rhabdomyolysis]]
|-
|- bgcolor="lightsteelblue"
| '''Neurologic'''
| bgcolor="beige" | No underlying causes
|-
|- bgcolor="lightsteelblue"
| '''Nutritional/Metabolic'''
| bgcolor="beige" | [[obesity|extreme obesity]]
|-
|- bgcolor="lightsteelblue"
| '''Obstetric/Gynecologic'''
| bgcolor="beige" | [[Eclampsia]], [[preeclampsia]]
|-
|- bgcolor="lightsteelblue"
| '''Oncologic'''
| bgcolor="beige" | [[Renal cell carcinoma]], [[multiple myeloma]]
|-
|- bgcolor="lightsteelblue"
| '''Ophthalmologic'''
| bgcolor="beige" | No underlying causes
|-
|- bgcolor="lightsteelblue"
| '''Overdose/Toxicity'''
| bgcolor="beige" | No underlying causes
|-
|- bgcolor="lightsteelblue"
| '''Psychiatric'''
| bgcolor="beige" | [[stress]]
|-
|- bgcolor="lightsteelblue"
| '''Pulmonary'''
| bgcolor="beige" | No underlying causes
|-
|- bgcolor="lightsteelblue"
| '''Renal/Electrolyte'''
| bgcolor="beige" | [[Amyloidosis]], [[Bence jones protein|Bence-jones proteinuria]], [[crescentic glomerulonephritis]], [[dehydration]], [[Fanconi syndrome]], [[fibrillary glomerulopathies]], [[focal segmental glomerulosclerosis ]] , [[hyperoxaluria]], [[hypertension-related kidney failure]], [[hyperuricemia]], [[hypokalemic nephropathy]],  [[interstitial nephritis]], [[medullary cystic kidney disease]], [[myoglobinuria]], [[nephritic syndrome]], [[nephritis of pregnancy]], [[nephrotic syndrome)]], [[Papillary necrosis]], [[polycystic kidney disease|autosomal dominant polycystic kidney disease )]], [[Poststreptococcal glomerulonephritis]], [[Proliferative glomerulonephritis]], [[Proximal renal tubular acidosis]], [[acute Pyelonephritis]], [[renal artery stenosis]], [[renal metastases]], [[renal neoplasm]], [[renal tubular acidosis]], [[renal vein thrombosis]], [[rhabdomyolysis]], [[toxic nephropathy]], [[unilateral kidney]], [[Urinary tract infection]], [[X-linked hypophosphataemia]]
|-
|- bgcolor="lightsteelblue"
| '''Rheumatology/Immunology/Allergy'''
| bgcolor="beige" | [[Allergens]], [[arteriolar nephrosclerosis]], [[autoimmune conditions]], [[Bence-jones proteinuria]], [[Collagen vascular diseases]], [[crescentic glomerulonephritis]], [[Fanconi syndrome]], [[fibrillary glomerulopathies]], [[focal segmental glomerulosclerosis )]], [[Henoch-schonlein syndrome]], [[hepatitis b]],  [[IgA nephropathy (i.e.,  Berger's disease)]], [[IgM nephropathy]], [[increased formation of polyclonal free light chains]], [[interstitial nephritis]], [[mixed cryoglobulinemia]], [[multiple myeloma]], [[Organ rejection- kidney transplant patients]]], [[Polyarteritis nodosa]], [[recurrent hereditary polyserositis]], [[rheumatoid disease]], [[sarcoidosis]], [[systemic lupus erythematosis]], [[systemic sclerosis]], [[Wegener's granulomatosis]]
|-
|- bgcolor="lightsteelblue"
| '''Sexual'''
| bgcolor="beige" | No underlying causes
|-
|- bgcolor="lightsteelblue"
| '''Trauma'''
| bgcolor="beige" | [[musculoskeletal trauma]]
|-
|- bgcolor="lightsteelblue"
| '''Urologic'''
| bgcolor="beige" | [[Retrograde ejaculation]]
|-
|- bgcolor="lightsteelblue"
| '''Miscellaneous'''
| bgcolor="beige" | No underlying causes
|-
|}
<small>
===Causes in Alphabetical Order===
<small>
{{col-begin|width=84%}}
{{col-break|width=33%}}
*[[Acute pyelonephritis]]
*[[Aflibercept]]
*[[Allergens]]
*[[Alport syndrome]]
*[[Alström syndrome]]
*[[Aminoaciduria]]
*[[Amyloidosis]]
*[[Anticonvulsants]]
*[[Arteriolar nephrosclerosis]]
*aristolochic acids
*[[Artemether and lumefantrin]]
*[[Autoimmune conditions]]
*[[Autosomal dominant conditions]]
*[[Autosomal dominant polycystic kidney disease]]
*[[Autosomal recessive conditions]]
*[[Bacteria and bacterial conditions]]
*[[Balkan endemic nephropathy]]
*[[Bence-jones proteinuria]]
*[[Benign orthostatic (postural) proteinuria]]
*[[Bevacizumab]]
*[[Bromobenzene]]
*[[cadmium]]<ref name="pmid13680539">{{cite journal| author=Van Vleet TR, Schnellmann RG| title=Toxic nephropathy: environmental chemicals. | journal=Semin Nephrol | year= 2003 | volume= 23 | issue= 5 | pages= 500-8 | pmid=13680539 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13680539  }} </ref>
*[[Captopril]]
*[[Carmustine]]
*[[Caspofungin]]
*[[Chronic lymphocytic leukemia]]
*[[Chronic pyelonephritis]]
*Choloroform
*[[Circulatory failure]]
*[[Cirrhosis of liver]]
*[[Cisplatin]]
*[[Collagen vascular disease]]
*[[Congenital conditions]]
*[[Connatal tulbulopathies]]
*[[Constrictive pericarditis]]
*[[Crescentic glomerulonephritis]]
*[[Cystinosis]]
*[[Cystitis]]
*[[Cytomegalovirus]]
*[[Deferasirox]]
*[[Dehydration]]
*[[Dent disease]]
*[[Diabetes mellitus]]
*Diquat
*[[Ebola hemorrhagic fever]]
*[[Eclampsia]]
*[[Epstein-Barr virus]]
*[[Ethylene glycol]]
*[[Exercise-induced]]
*[[Fabry's disease]]
*[[Familial mediterranean fever]]
*[[Fanconi syndrome]]
*[[Fibrillary glomerulopathies]]
{{col-break|width=33%}}
*[[Focal segmental glomerulosclerosis]]
*[[Galactosemia]]
*[[Gemcitabine]]
*[[Genitourinary tuberculosis]]
*[[Glycogen storage disease type I]]
*[[Gold]]
*[[Heavy metal ingestion]]
*[[Helminthic]]
*[[Hemoglobinuria]]
*[[Henoch-Schonlein syndrome]]
*[[Hepatitis B]]
*[[Hepatorenal tyrosinemia]]
*[[Hereditary fructose intolerance]]
*[[Heroin]]
*[[High blood pressure]]
*[[High fever]]
*[[HIV]]
*[[Hyperoxaluria]]
*[[Hypertension-related kidney failure]]
*[[Hyperuricaemia]]
*[[Hypokalemic nephropathy]]
*[[Hypothyroidism]]
*[[Idiopathic multicentric osteolysis]]
*[[IgA nephropathy (i.e., Berger's disease)]]
*[[IgM nephropathy]]
*[[Imerslund-Gräsbeck syndrome]]
*[[Increased formation of polyclonal free light chains]]
*[[Infectious Mononucleosis]]
*[[Interferon gamma]]
*[[Interstitial nephritis]]
*[[Irradiation]]
*[[Lecithin cholesterol acyltransferase deficiency]]
*[[Legionella Pneumophila]]
*[[Leprosy]]
*[[Lomustine]]
*[[Malaria]]
*[[Malignancies (e.g., lymphoma, other cancers)]]
*[[Massive obesity]]
*[[Medullary cystic kidney disease]]
*[[Mercury]]<ref name="pmid13680539">{{cite journal| author=Van Vleet TR, Schnellmann RG| title=Toxic nephropathy: environmental chemicals. | journal=Semin Nephrol | year= 2003 | volume= 23 | issue= 5 | pages= 500-8 | pmid=13680539 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13680539  }} </ref>
*[[Micafungin]]
*[[Mithramycin]]
*[[Mixed cryoglobulinemia]]
*[[Multiple myeloma]]
*[[Myoglobinuria]]
*[[Nail patella syndrome]]
*[[Nephritic syndrome]]
*[[Nephritis of pregnancy]]
{{col-break|width=33%}}
*[[Nephrolithiasis]]
*[[Nephrotic syndromes]]
*[[Nitrosourea compounds]]
*[[NSAIDS]]
*[[Nutcracker syndrome of left renal vein]]
*[[Obstetric conditions]]
*[[Orthostatic proteinuria]]
*[[Oxaprozin]]
*[[Papillary necrosis]]
*paraquat
*[[Pazopanib]]
*[[Penicillamine]]
*[[Polyarteritis nodosa]]
*[[Poststreptococcal glomerulonephritis]]
*[[Preeclampsia]]
*[[Proliferative glomerulonephritis]]
*[[Prostatitis]]
*[[Proximal renal tubular acidosis]]
*[[Recurrent hereditary polyserositis]]
*[[Renal artery stenosis]]
*[[Renal metastases]]
*[[Renal neoplasm]]
*[[Renal tubular acidosis]]
*[[Renal vein thrombosis]]
*[[Retrograde ejaculation]]
*[[Rhabdomyolysis]]
*[[Rheumatoid disease]]
*[[Sarcoidosis]]
*[[Shock]]
*[[Sickle cell disease]]
*[[Sorafenib]] 
*[[Streptozocin]]
*[[Stress]]
*[[Subacute bacterial endocarditis]]
*[[Sulphasalazine]]
*[[Systemic lupus erythematosis]]
*[[Systemic sclerosis]]
*[[Telavancin hydrochloride]]
*[[Toxic nephropathy]]
*[[Toxoplasmosis]]
*[[Transplant rejection]]
*[[Tricuspid insufficiency]]
* Tricholoroethelene
*[[Unilateral kidney]]
*[[Urinary tract infection]]
*[[Vasculitis]]
*[[Viral]]
*[[Waldenstrom's macroglobulinemia]]
*[[Wegener's granulomatosis]]
*[[Wilson's disease]]
*[[X-linked hypophosphatemia]]
*[[Yellow fever]]
{{col-end}}
</small>


==References==  
==References==  

Revision as of 15:54, 8 August 2018

WikiDoc Resources for Proteinuria

Articles

Most recent articles on Proteinuria

Most cited articles on Proteinuria

Review articles on Proteinuria

Articles on Proteinuria in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Proteinuria

Images of Proteinuria

Photos of Proteinuria

Podcasts & MP3s on Proteinuria

Videos on Proteinuria

Evidence Based Medicine

Cochrane Collaboration on Proteinuria

Bandolier on Proteinuria

TRIP on Proteinuria

Clinical Trials

Ongoing Trials on Proteinuria at Clinical Trials.gov

Trial results on Proteinuria

Clinical Trials on Proteinuria at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Proteinuria

NICE Guidance on Proteinuria

NHS PRODIGY Guidance

FDA on Proteinuria

CDC on Proteinuria

Books

Books on Proteinuria

News

Proteinuria in the news

Be alerted to news on Proteinuria

News trends on Proteinuria

Commentary

Blogs on Proteinuria

Definitions

Definitions of Proteinuria

Patient Resources / Community

Patient resources on Proteinuria

Discussion groups on Proteinuria

Patient Handouts on Proteinuria

Directions to Hospitals Treating Proteinuria

Risk calculators and risk factors for Proteinuria

Healthcare Provider Resources

Symptoms of Proteinuria

Causes & Risk Factors for Proteinuria

Diagnostic studies for Proteinuria

Treatment of Proteinuria

Continuing Medical Education (CME)

CME Programs on Proteinuria

International

Proteinuria en Espanol

Proteinuria en Francais

Business

Proteinuria in the Marketplace

Patents on Proteinuria

Experimental / Informatics

List of terms related to Proteinuria

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Saeedeh Kowsarnia M.D.[2]

Synonyms and keywords: Elevated urinary protein levels; Elevated urine protein

To view a comprehensive algorithm of common findings of urine composition and urine output, click here

Overview

Excretion of the proteins in the urine may suggest variety of medical conditions from benign to severe kidney injury. The amount of proteinuria can be used as a clue to estimate the site and the cause of proteinuria. Three factors which are involved in development of proteinuria are glomerular-capillary barrier, tubular reabsorption capability, and protein's characteristics.

Classification

Proteinuria is classified based upon the site and the amount of protein in the urine.[1]

Types Definition Level of proteinuria
Glomerular proteinuria Increased filtration rate of protein due to the damage to the glomerular-capillary barrier. Variable,

usually > 2g/day

Dipstick:Positive

Tubular proteinuria Decreased tubular reabsorption of proteins due to tubular cell damage. < 2 g/day

Dipstick:Negative

Overflow proteinuria Increased urinary excretion of proteins due to exceeding reabsorption capacity of renal tubules. Variable up to 20g/day

Dipstick:Negative

Post-renal proteinuria Increased urinary excretion of the small amount of protein especially IgA and IgG. Variable,

usually < 1g/day

Isolated proteinuria Proteinuria with normal urinary sediment with no history of renal disease. < 2 g/day
Proteinuria Amount
Normal range Total protein excretion in urine (proteinuria): < 150 mg/day, average 80 mg/day

Albumin excretion: < 20 mg/day (15 mcg/min), 15% of urine total protein

(remaining 85% constitutes Tamm-Horsfall proteins, IgA, urokinase) [2][3]

(The rate of proteinuria increases proportionally with age and body weight)

Albuminuria

(microalbuminuria)

30-300 mg/day (20 to 200 mcg/min)
Overt proteinuria

(macroalbuminuria)

Albuminuria > 300 mg/day (200 mcg/min) up to 3500 mg/day, positive dipstick
Nephrotic range Total protein excretion: ≥ 3.5 g/day

Albumin–to-creatinine ratio: > 3-3.5 mg protein/mg creatnine

Pathophysiology

  • The amount of proteins present in the urine is < 150 mg/day with an intact glomerular-capillary barrier and functioning tubules, thus increased levels of proteinuria can demonstrate kidney damage (glomerular or tubular).
  • Overproduction of proteins which exceeds the absorption capacity of the tubules causes proteinuria in spite of relatively normal renal function (overflow).
  • Normally filtration of all plasma proteins like albumin, globulins and other high-molecular-weight proteins through the glomerular-capillary wall is prevented by charge and size of the proteins and glomerular-capillary barrier .
  • The type and quantity of proteins in the urine may identify the etiology and site of kidney damage.
  • As injury to the glomerular-capillary barrier causes albuminuria, tubular damage and overflow proteinuria lead to increase loads of low-molecular-weight proteins in the urine.
  • The severity of protein loss in the urine depends on the mechanism of renal injury.

Glomerular-capillary barrier

Tubular reabsorption

  • Almost all the proteins which are filtered through glomerulus are reabsorbed by proximal tubular cells by endocytosis.
  • The tubulointerstitial diseases damage the cells cause tubular proteinuria.
  • In circumstances where large amounts of protein is filtered, tubular proteinuria occurs as the filtered protein exceeds the reabsorption capacity of the cells.
  • Not all the proteins in the tubules are toxic to the cells but proximal tubule injury, light chain deposition, and tubule obstruction (cast nephropathy) due to the large amount of light chain may cause further proteinuria by the overwhelming capacity of tubular cells.

Proteins

  • The size of the protein is one of the determinants of traversal through the glomerular-capillary barrier. Immunoglobulins like IgG and other high-molecular-weight proteins have the higher molecular radius, therefore, there are not able to pass over the barrier.
  • Low-molecular-weight proteins are the ones with < 40kDa and molecular radius < 30 Å are filtered almost completely and reabsorbed by tubular cells.[5]
  • In normal physiological condition, HMW proteins do not cross the glomerular barrier. The small percentage of albumin passes the barrier which is reabsorbed completely in the proximal tubules. LMW proteins are filtered and reabsorbed completely. [6]
  • Moderate alteration of permeability of glomerular barrier named as selective proteinuria, demonstrates with loss of negative-charged proteins like albumin, LMW proteins and small percentage of HMW proteins in the urine with exceeding the reabsorption capacity of tubular cells.
  • Severe damage to the barrier causes loss of the greater percentage of HMW proteins in the urine which is called nonselective proteinuria.
  • Profound damage to glomerular barrier causes severe proteinuria of all classes especially LMW and HMW. Increasing loads of protein which exceed the reabsorption capability of tubular cells causes damage to tubular cells and worsens proteinuria.

(an average protein has 250 amino acids which equals molecular weight( MW) of approximately 34 kDa)

Glomerular-capillary wall, (ɔ) Image courtesy of WikiDoc.org, by "Saeedeh Kowsarnia M.D."

Causes

For more details on the causes of glomerular proteinuria, click here.

For more details on the causes of tubular proteinuria, click here.

Classification Etiology
Glomerular proteinuria Diabetic nephropathy, orthostatic proteinuria, glomerulonephropathies, hypertensive nephrosclerosis, preeclampsia, collagen vascular disease, infections, cancer, lymphoma, chronic renal transplant rejection, drugs, amyloidosis, post-transplant proteinuria

Transient: Exercise-induced proteinuria, fever, Infection, heart failure, joint inflammation, hyperlipidemia (LDL > 120 mg/dL), hyperglycemia (HbA1c > 8%), hypertension (BP >160/100 mmHg)

Tubular proteinuria Tubulointerstitial diseases, cryoglobulinemia, Sjögren's syndrome, immunosuppressive agents, analgesic use

Excluding criteria: Proteinuria (≥ 3.5 g/day), edema, hypoalbuminemia, lipiduria, active urine sediment

(red blood cells and/or cast), decreased GFR, hypertension

Overflow proteinuria Light chains of immunoglobulins (multiple myeloma), lysozyme (AML), myoglobin (rhabdomyolysis), free hemoglobin not bound to haptoglobin (intravascular hemolysis), lymphoma, amyloidosis
Post-renal proteinuria Nephrolithiasis, urinary tract tumors or infections
Isolated proteinuria Damage to tubular cells or the lower urinary tract

There is a 20% risk for developing renal insufficiency in the next 10 years, close follow up with blood pressure measurement, urinalysis and creatinine clearance every 6 months [7]

Microalbuminuria

Essential hypertension, early diabetes, early stages of glomerulonephritis (especially with active sediments; RBCs, RBC casts)

Macroalbuminuria

Fever, exercise, CHF, orthostatic proteinuria, intermittent proteinuria, the kidney disease associated with myeloma, all diseases which are mentioned as the causes of microalbuminuria

Nephrotic range proteinuria Diabetes, minimal change disease, amyloidosis, FSGS, membranous glomerulopathy, IgA nephropathy

Risk Factors

The risk factors for proteinuria include:

Screening

  • Urinalysis may be considered as a part of routine health evaluation.
  • Monitor of renal function and proteinuria (micro- and microalbuminuria) is recommended in individuals with systemic diseases who are at risk of proteinuria.

Epidemiology and Demographics

  • Prevalence of albuminuria is 6100 and 9700 per 100,000 in male and female population, respectively.[12]
  • The estimated prevalence rate of albuminuria among diabetes population is 28,800 per 100,000 individuals.
  • The estimated prevalence rate of albuminuria among hypertensive population is 16,000 per 100,000 individuals.
  • Isolated albuminuria with normal renal function is estimated 3,300 per 100,000 adult population.

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

Diagnosis

Diagnostic Study of Choice

Qualitative measures

  • Urine dipstick:
    • The standard urine dipstick is sensitive to urine albumin not to the non-albumin proteins, so the positive result indicates glomerular proteinuria.
    • The dipstick grading is semiquantitative to the amount of protein in the urine and is dependent upon urine concentration.
    • The sensitivity of the urinary dipstick for detection of albumin in the urine ranges from 83% to 98% with a specificity of 59% to 86%.[15]
    • At the lower level of albuminuria, especially microalbuminuria the urine dipstick is specific but not sensitive, therefore microalbuminuria cannot be detected easily by urine dipstick unless the urine is properly concentrated.
    • Few data suggests using specific gravity to estimate the amount of proteinuria, especially with the dipstick result of trace or 1+.
    • Highly concentrated urine overestimates the amount of proteinuria in the urine, similarly, highly diluted urine underestimates the degree of proteinuria detected by dipstick.
    • False-positive result: Urine PH > 8, administration of radiocontrast agents (iodinated), gross hematuria.
    • Newer dipsticks can detect albumin-to-creatinine and total protein-to-creatinine ratios which can help to avoid errors associated with diluted or concentrated urines and non-albumin proteinuria, respectively.
  • Sulfosalicylic acid test (SSA): Use of SSA is indicated in patients with the possibility of myeloma in the presence of negative or trace dipstick with renal function impairment. Adding SSA to the urine precipitates all proteins, therefore positive dipstick with SSA demonstrates overflow or tubular proteinuria.


Reference range for proteinuria Standard dipstick +/- SSA
Trace Slight turbidity (1 to 10 mg/dL)
1+ Turbidity through which print can be read (15 to 30 mg/dL)
2+ White cloud without precipitate through which print can be seen (40 to 100 mg/dL)
3+ White cloud with fine precipitate through which print cannot be seen (150 to 350 mg/dL)
4+ Fluffy precipitate (>500 mg/dL)

Quantitative measures

  • 24-hour urine collection:
    • It is the gold standard test to determine the amount of proteinuria in patients who presents with persistent proteinuria (normal value < 150 mg/day). As collecting urine for 24 is cumbersome and erroneous, spot urine of first and second morning samples with protein-creatinine ratio can be used as an estimate of total protein excretion in 24 hour.[16]
24-hour protein excretion= Urine protein concentration / Urine creatinine concentration
  • Urine creatinine is higher in individuals with higher body muscle mass, therefore urine-protein ratio underestimates proteinuria, similarly in cachectic patients with lower muscle mass, urine-protein ratio overestimates the degree of proteinuria.
  • Renal biopsy: Renal biopsy is indicated in:
    • All nephrotic range proteinuria (> 3.5 gr/day)
    • Non-nephrotic range proteinuria with:
      • Active urine sediment
      • Persistent proteinuria > 1 gr/day
      • Decreased GFR
      • Progression of proteinuria or developing active sediment or hypertension

History and Symptoms

History:

Symptoms:

Physical Examination

Laboratory Findings

Laboratory investigations to be considered in proteinuria:

Treatment

Medical Therapy

Specific treatments of proteinuria demands proper diagnosis of the causes.

For the details on the treatments of glomerular diseases, click here.

For the details on the treatments of tubular diseases, click here.

Non-specific treatments reduce the amount of proteinuaria and the rate of progression or address the complications of proteinuria.

  • Diuretics:
    • The treatment of fluid overload in patients with moderate to severe proteinuria along with salt restriction is diuretics.
    • For refractory cases two different class of diuretics are used if the increasing doses are not effective.[17]
    • Acute renal failure is the consequence of aggressive therapy with diuretics.
  • ACE inhibitors and ARBs:
    • These agents decrease the progression and the amount of proteinuria by decreasing the intraglomerular pressure.[18]
    • Inhibiting vasoconstriction of efferent arterioles, maintaining the glomerular-capillary wall and decreasing the sclerosis and fibrosis of glomerulus are the action of these drugs aside the anti-hypertensive effects.[19]
    • In normotensive individuals with proteinuria low dose of these drugs have the effect without evident hypotension.[20]
    • Adverse effects of ACE inhibitors are cough, angioedema and hyperkalemia.
  • Mineralocorticoind receptor antagonists
    • Adding mineralocorticoid receptor antagonists like eplerenone and spironolactone, help reducing proteinuria further but increase the rate of hyperkalemia.
    • Eplerenone is the new drug in this category which is not associated with hyperkalemia.

Primary Prevention

  • Primary prevention of proteinuria includes early diagnosis and treatment of diseases which lead to proteinuria.

Secondary Prevention

  • Effective measures for secondary prevention of proteinuria include:
    • Monitor the level of proteinuria to assess the progression of the disease
    • Monitor and treat lipid abnormalities
    • Check for effectiveness of the therapy and medications' side effects
    • Monitor the renal function regularly
    • Monitor and treat the complications of proteinuria
    • Monitor for new signs of other diseases to address the treatment properly

Related Chapters

References

  1. Venkat, K K. (2004). "Proteinuria and Microalbuminuria in Adults: Significance, Evaluation, and Treatment". Southern Medical Journal. 97 (10): 969–979. doi:10.1097/01.SMJ.0000140833.51533.46. ISSN 0038-4348.
  2. Viswanathan, Gautham; Upadhyay, Ashish (2011). "Assessment of Proteinuria". Advances in Chronic Kidney Disease. 18 (4): 243–248. doi:10.1053/j.ackd.2011.03.002. ISSN 1548-5595.
  3. . doi:10.3265/Nefrologia.pre2011.Jan.10807. Missing or empty |title= (help)
  4. Toblli, Jorge E.; Bevione, P.; Di Gennaro, F.; Madalena, L.; Cao, G.; Angerosa, M. (2012). "Understanding the Mechanisms of Proteinuria: Therapeutic Implications". International Journal of Nephrology. 2012: 1–13. doi:10.1155/2012/546039. ISSN 2090-214X.
  5. D'Amico, Giuseppe; Bazzi, Claudio (2003). "Pathophysiology of proteinuria". Kidney International. 63 (3): 809–825. doi:10.1046/j.1523-1755.2003.00840.x. ISSN 0085-2538.
  6. Toblli, Jorge E.; Bevione, P.; Di Gennaro, F.; Madalena, L.; Cao, G.; Angerosa, M. (2012). "Understanding the Mechanisms of Proteinuria: Therapeutic Implications". International Journal of Nephrology. 2012: 1–13. doi:10.1155/2012/546039. ISSN 2090-214X.
  7. Abuelo JG (1983). "Proteinuria: diagnostic principles and procedures". Ann Intern Med. 98 (2): 186–91. PMID 6824253.
  8. Bryson, Chris L.; Ross, Heather J.; Boyko, Edward J.; Young, Bessie A. (2006). "Racial and Ethnic Variations in Albuminuria in the US Third National Health and Nutrition Examination Survey (NHANES III) Population: Associations With Diabetes and Level of CKD". American Journal of Kidney Diseases. 48 (5): 720–726. doi:10.1053/j.ajkd.2006.07.023. ISSN 0272-6386.
  9. Rosenstock, Jordan L.; Pommier, Max; Stoffels, Guillaume; Patel, Satyam; Michelis, Michael F. (2018). "Prevalence of Proteinuria and Albuminuria in an Obese Population and Associated Risk Factors". Frontiers in Medicine. 5. doi:10.3389/fmed.2018.00122. ISSN 2296-858X.
  10. Ong, Loke Meng; Punithavathi, Narayanan; Thurairatnam, Dharminy; Zainal, Hadzlinda; Beh, Mei Li; Morad, Zaki; Lee, Sharleen YS; Bavanandan, Sunita; Kok, Lai Sun (2013). "Prevalence and risk factors for proteinuria: The National Kidney Foundation of Malaysia Lifecheck Health Screening programme". Nephrology. 18 (8): 569–575. doi:10.1111/nep.12112. ISSN 1320-5358.
  11. Bhalla, V.; Zhao, B.; Azar, K. M. J.; Wang, E. J.; Choi, S.; Wong, E. C.; Fortmann, S. P.; Palaniappan, L. P. (2012). "Racial/Ethnic Differences in the Prevalence of Proteinuric and Nonproteinuric Diabetic Kidney Disease". Diabetes Care. 36 (5): 1215–1221. doi:10.2337/dc12-0951. ISSN 0149-5992.
  12. Jones, Camille A.; Francis, Mildred E.; Eberhardt, Mark S.; Chavers, Blanche; Coresh, Josef; Engelgau, Michael; Kusek, John W.; Byrd-Holt, Danita; Narayan, K.M.Venkat; Herman, William H.; Jones, Camara P.; Salive, Marcel; Agodoa, Lawrence Y. (2002). "Microalbuminuria in the US population: Third National Health and Nutrition Examination Survey". American Journal of Kidney Diseases. 39 (3): 445–459. doi:10.1053/ajkd.2002.31388. ISSN 0272-6386.
  13. Astor, Brad C.; Matsushita, Kunihiro; Gansevoort, Ron T.; van der Velde, Marije; Woodward, Mark; Levey, Andrew S.; Jong, Paul E. de; Coresh, Josef (2011). "Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts". Kidney International. 79 (12): 1331–1340. doi:10.1038/ki.2010.550. ISSN 0085-2538.
  14. Borrego, J.; Mazuecos, A.; Gentil, M.A.; Cabello, M.; Rodríguez, A.; Osuna, A.; Pérez, M.A.; Castro, P.; Alonso, M. (2013). "Proteinuria as a Predictive Factor in the Evolution of Kidney Transplantation". Transplantation Proceedings. 45 (10): 3627–3629. doi:10.1016/j.transproceed.2013.10.025. ISSN 0041-1345.
  15. Mark J. Siedner, Allan C. Gelber, Brad H. Rovin, Alison M. McKinley, Lisa Christopher-Stine, Brad Astor, Michelle Petri & Derek M. Fine (2008). "Diagnostic accuracy study of urine dipstick in relation to 24-hour measurement as a screening tool for proteinuria in lupus nephritis". The Journal of rheumatology. 35 (1): 84–90. PMID 18085740. Unknown parameter |month= ignored (help)
  16. Mark J. Siedner, Allan C. Gelber, Brad H. Rovin, Alison M. McKinley, Lisa Christopher-Stine, Brad Astor, Michelle Petri & Derek M. Fine (2008). "Diagnostic accuracy study of urine dipstick in relation to 24-hour measurement as a screening tool for proteinuria in lupus nephritis". The Journal of rheumatology. 35 (1): 84–90. PMID 18085740. Unknown parameter |month= ignored (help)
  17. Fukuda, Michio; Kimura, Genjiro (2008). "Diuretics should be used as the second-line agent in combination with RAS inhibitors in ptoteinuric patients with CKD". Kidney International. 74 (10): 1358. doi:10.1038/ki.2008.466. ISSN 0085-2538.
  18. Hsu, Feng-Yi; Lin, Fang-Ju; Ou, Huang-Tz; Huang, Shih-Hui; Wang, Chi-Chuan (2017). "Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria". Kidney and Blood Pressure Research. 42 (2): 358–368. doi:10.1159/000477946. ISSN 1420-4096.
  19. Toblli, Jorge E.; Bevione, P.; Di Gennaro, F.; Madalena, L.; Cao, G.; Angerosa, M. (2012). "Understanding the Mechanisms of Proteinuria: Therapeutic Implications". International Journal of Nephrology. 2012: 1–13. doi:10.1155/2012/546039. ISSN 2090-214X.
  20. Gansevoort RT, de Zeeuw D, de Jong PE (1996). "ACE inhibitors and proteinuria". Pharm World Sci. 18 (6): 204–10. PMID 9010883.
  21. Toto, Robert D.; Tian, Min; Fakouhi, Kaffa; Champion, Annette; Bacher, Peter (2008). "Effects of Calcium Channel Blockers on Proteinuria in Patients With Diabetic Nephropathy". The Journal of Clinical Hypertension. 10 (10): 761–769. doi:10.1111/j.1751-7176.2008.00016.x. ISSN 1524-6175.
  22. Katsuyuki Ando (2013). "L-/N-type calcium channel blockers and proteinuria". Current hypertension reviews. 9 (3): 210–218. PMID 24479751. Unknown parameter |month= ignored (help)
  23. . doi:10.3265/Nefrologia.pre2013.Apr.12025. Missing or empty |title= (help)

Template:Abnormal clinical and laboratory findings

Template:WH Template:WS